Beyond Air, Inc. Stock News

Contract awarded for products that bring improvement to health care industry Contract awarded for products that bring improvement to health care industry

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide

GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at 9:00 a.m. EDT Abstract titles to be presented at the Society for Immuno

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor

The realm of penny stocks, often characterized by their affordable price tag, has become a hotspot for investors eager to seize the stock market's opportunities. These stocks, typically valued under $

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Of

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.37 per share a year ago.

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

Today, we take a look at an interesting small-cap medical device concern called Beyond Air, Inc. The company is just rolling out its first approved product and has other assets in development. However

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2023 Earnings Conference Call June 22, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Offi

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.26 per share a year ago.

GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for

According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks that have high number of unique insider buys over the past three months are Air Transport Services Group Inc.

Proffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDT Proffered abstracts accepted for present